Evidence map›Paper›PMID 33086792›Full record

ArticleAnalytical chemistry2020

Cross-validated Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry Imaging Quantitation Protocol for a Pharmaceutical Drug and Its Drug-Target Effects in the Brain Using Time-of-Flight and Fourier Transform Ion Cyclotron Resonance Analyzers.

Patrik Källback, Theodosia Vallianatou, Anna Nilsson, Reza Shariatgorji, Nicoletta Schintu, Marcela Pereira, Florian Barré, Henrik Wadensten, Per Svenningsson, Per E Andrén

Open access · hybridAbstract read
In one paragraph

Article in Analytical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Spatial pharmacology using mass spectrometry imaging.Trends in pharmacological sciences · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Patrik KällbackMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Theodosia VallianatouMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Anna NilssonMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Reza ShariatgorjiMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.ORCID 0000-0001-9484-0921
Nicoletta SchintuDepartment of Neurology and Clinical Neuroscience, Karolinska Institutet and Karolinska University Hospital, 17176, Stockholm, Sweden.
Marcela PereiraDepartment of Neurology and Clinical Neuroscience, Karolinska Institutet and Karolinska University Hospital, 17176, Stockholm, Sweden.
Florian BarréMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Henrik WadenstenMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.
Per SvenningssonDepartment of Neurology and Clinical Neuroscience, Karolinska Institutet and Karolinska University Hospital, 17176, Stockholm, Sweden.
Per E AndrénMedical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, BMC 591, 75124 Uppsala, Sweden.ORCID 0000-0002-4062-7743
Uppsala University · SEKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) is an established tool in drug development, which enables visualization of drugs and drug metabolites at spatial localizations in tissue sections from different organs. However, robust and accurate quantitation by MALDI-MSI still remains a challenge. We present a quantitative MALDI-MSI method using two instruments with different types of mass analyzers, i.e., time-of-flight (TOF) and Fourier transform ion cyclotron resonance (FTICR) MS, for mapping levels of the

Indexed as

CyclotronsFourier AnalysisAnimalsBrainCalibrationChromatography, LiquidCitalopramHippocampusMaleMiceReproducibility of ResultsSerotoninSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationCitalopramSerotonin

Identifiers

PMID33086792
PMCPMC7660593
OpenAlexW3093690405

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.